Interv Akut Kardiol. 2006;5(1):37-39
OASIS-5
- Kardio-Troll, pracoviště invazivní kardiologie, Krajská nemocnice, Pardubice
Indirect factor Xa inhibitor fondaparinux was compared with enoxaparin in the treatment of patients with acute coronary syndrome without ST elevation. The efficacy of fondaparinux was comparable with enoxaparin in terms of death, nonfatal myocardial infarction and refractory ischaemia on Day 9. The incidence of major bleeding complications was doubled with enoxaparin treatment. The increase in bleeding complications was then associated with a higher mortality in enoxaparin-treated patients in the following months.
Keywords: fondaparinux, enoxaparin, NSTEMI, bleeding complications
Published: January 1, 2006 Show citation
